All In Biotech

Drug Trial Radar · NCT05936359

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

160

Actual

Start

Sep 25, 2023

Primary completion

Feb 29, 2028

Study completion Feb 29, 2028

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Jul 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.

Conditions

  • Myeloproliferative Neoplasms

Interventions

  • INCA033989Drug

    INCA033989 will be administered at protocol defined dose.

  • RuxolitinibDrug

    Rux will be administered according to Prescribing Information/SmPC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
  2. Number of participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 3 years and 60 days
  3. Number of participants with TEAEs leading to dose modification or discontinuationTime frame: Up to 3 years and 60 days

Locations

28 sites in 9 countries. Site status is shown where the registry gives one.

  • Royal Brisbane and Women'S Hospital

    Herston, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Hopital Maisonneuve-Rosemont, Montreal, Qc

    Montreal, Quebec, Canada

  • Sjaellands Universitetshospital

    Roskilde, Denmark

  • Vejle Hospital

    Vejle, Denmark

  • Institut Bergonie

    Bordeaux, France

  • Chu Nimes

    Nîmes, France

  • Hospital Saint Louis

    Paris, France

  • Institut Gustave Roussy

    Villejuif, France

  • University Medical Center Rwth Aachen

    Aachen, Germany

  • Universitatsklinikum Halle (Saale)

    Halle, Germany

  • Universitätsklinikum Ulm

    Ulm, Germany

  • Aou Policlinico S. Orsola-Malpighi

    Bologna, Italy

  • Azienda Ospedaliero-Universitaria Careggi (Aouc)

    Florence, Italy

  • Fondazione Irccs Ca Granda Ospedale Maggiore

    Milan, Italy

  • National Cancer Center Hospital East

    Chiba-ken, Japan

  • Kagoshima University Hospital

    Kagoshima, Japan

  • Osaka Metropolitan University Hospital

    Osaka, Japan

  • Nippon Medical School Hospital

    Tokyo, Japan

  • Mie University Hospital

    Tsu, Japan

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitari I Politecnic La Fe

    Valencia, Spain

  • Guys and St Thomas Nhs Foundation Trust

    London, United Kingdom

  • The Christie Nhs Foundation Trust Uk

    Manchester, United Kingdom

  • University of Oxford

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.